BACKGROUND/AIM: The role of anti-PD1/PD-L1 therapy (IO) in NSCLC harboring driver mutations is questionable. This study aimed to examine the efficacy of IO in patients with non-small cell lung cancer (NSCLC) with a KRAS mutation (KRAS+). PATIENTS AND METHODS: We retrospectively identified NSCLC patients harboring KRAS mutation treated with IO in our Institution. We analyzed the results in comparison to non-KRAS patients. RESULTS: Among 328 consecutive KRAS+ NSCLC patients, 43 (13.1%) received IO in our Institution. In parallel 117 non-KRAS NSCLC patients treated with IO were selected for comparison. The baseline characteristics were similar between the two groups. No significant difference was observed between KRAS+ and non-KRAS patients in terms of mPFS (4.6 vs. 3.3 months, p=0.58) or OS (8.1 vs. 13.0 months, p=0.38). CONCLUSION: KRAS mutations seem to be irrelevant for selecting patients for IO that could be therefore considered an effective therapy for NSCLC patients, independently of KRAS status. Copyright
BACKGROUND/AIM: The role of anti-PD1/PD-L1 therapy (IO) in NSCLC harboring driver mutations is questionable. This study aimed to examine the efficacy of IO in patients with non-small cell lung cancer (NSCLC) with a KRAS mutation (KRAS+). PATIENTS AND METHODS: We retrospectively identified NSCLCpatients harboring KRAS mutation treated with IO in our Institution. We analyzed the results in comparison to non-KRASpatients. RESULTS: Among 328 consecutive KRAS+ NSCLCpatients, 43 (13.1%) received IO in our Institution. In parallel 117 non-KRASNSCLCpatients treated with IO were selected for comparison. The baseline characteristics were similar between the two groups. No significant difference was observed between KRAS+ and non-KRASpatients in terms of mPFS (4.6 vs. 3.3 months, p=0.58) or OS (8.1 vs. 13.0 months, p=0.38). CONCLUSION:KRAS mutations seem to be irrelevant for selecting patients for IO that could be therefore considered an effective therapy for NSCLCpatients, independently of KRAS status. Copyright
Authors: Ella A Eklund; Clotilde Wiel; Henrik Fagman; Levent M Akyürek; Sukanya Raghavan; Jan Nyman; Andreas Hallqvist; Volkan I Sayin Journal: Cancers (Basel) Date: 2022-04-20 Impact factor: 6.575